Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35,  Peer-reviewed, Open-access Journal

A News Letter Sign UP!
COMPARATIVE STUDY OF EFFICACY AMONG TOCILIZUMAB, ETANERCEPT AND DISEASE MODIFYING DRUGS IN COMBINATION WITH METHOTREXATE: A SINGLE CENTER STUDY FROM LANZHOU, CHINA

Research Paper Open Access

International Journal of Latest Research in Science and Technology Vol.8 Issue 1, pp 1-4,Year 2019

COMPARATIVE STUDY OF EFFICACY AMONG TOCILIZUMAB, ETANERCEPT AND DISEASE MODIFYING DRUGS IN COMBINATION WITH METHOTREXATE: A SINGLE CENTER STUDY FROM LANZHOU, CHINA

Manisha Bhochhibhoya, Shen Haili , Binit Vaidya

Correspondence should be addressed to :

Received : 12 February 2019; Accepted : 20 February 2019 ; Published : 28 February 2019

Share
Download 126
View 184
Article No. 10963
Abstract

Purpose: The study aims to evaluate and compare the disease activities in Rheumatoid arthritis (RA) patients treated with MTX in combination with the conventional synthetic disease modifying antirheumatic drugs (csDMARD), Etanercept (ETC) and Tocilizumab (TCZ). Method: This was a prospective cohort study of patients with RA maintained at Second Hospital of Lanzhou University, Lanzhou from March 2016 to December 2018.Patients meeting criteria were grouped into three groups: group 1 treated with csDMARDs in combination with MTX (n=51), group 2 ETC in combination with MTX 2(n=49) and group 3 with TCZ in combination with MTX (n=50). Result: Of total patients (N=150), females were 72% (108/150) and the mean age at presentation was 43.3±9.9 years, 40.6±14.2 years, 38.2±14.7 years in group 1, 2 and 3 respectively. Baseline erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) of group 3 were statistically higher than group 1 and not different from group 2. The mean disease activity score (DAS) 28-ESR of group 1, 2 and 3 were 4.6±1.01, 4.9±0.91 and 5.3±2.0 respectively at baseline and 0.45±0.8, 0.57±0.89 and 2.16±1.5 respectively at 3months (p<0.001). The group 3 patients even though had higher baseline activity, there was a significant improvement in all parameters after 3 months as compared to other groups. Conclusion: TCZ in combination with MTX can be a good therapeutic option in treating moderate to severe RA compared to csDMARDs and ETC.

Key Words   
Rheumatoid Arthritis, Tocilizumab, Disease Activity, Interleukin-6 Inhibitor
Copyright
References
  1. Cross M, Smith E, Hoy D, Carmona L. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. 2014;73(7):1316-22.
  2. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-74.
  3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
  4. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S179-85.
  5. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. Jama. 2012;308(9):898-908.
  6. Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study G. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol. 2003;30(2):225-31.
  7. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063-74.
  8. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD open. 2015;1(Suppl 1):e000057.
  9. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43(10):1252-5.
  10. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-22-8.
  11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
  12. Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. BioMed research international. 2014;2014:831603.
  13. Singh JA, Cameron DR. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update. Journal of managed care pharmacy : JMCP. 2012;18(4 Supp C):S1-18.
  14. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S52-7.
  15. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82.
  16. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7.
  17. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
  18. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25.
  19. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803-9.
  20. Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35-43.
  21. Lauper K, Nordstrom DC, Pavelka K, Hernandez MV, Kvien TK, Kristianslund EK, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis. 2018;77(9):1276-82.
  22. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
  23. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21(2):122-33.
  24. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford). 2011;50(10):1908-15.
To cite this article

Manisha Bhochhibhoya, Shen Haili , Binit Vaidya , " Comparative Study Of Efficacy Among Tocilizumab, Etanercept And Disease Modifying Drugs In Combination With Methotrexate: A Single Center Study From Lanzhou, China ", International Journal of Latest Research in Science and Technology . Vol. 8, Issue 1, pp 1-4 , 2019

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.